title: Protective immunity in mice vaccinated with the Schistosoma mansoni P-28-1 antigen.
abstract: The P28-1 Ag induces a strong protective immunity toward Schistosoma mansoni infection in various experimental models. T lymphocytes of mice immunized with the recombinant P28-1 Ag were stimulated in vitro by schistosome Ag of different development stages and by three P28-1 Ag-derived synthetic peptides. The most significant stimulation was achieved with the 24-43 peptide. The use of two fragments of this peptide showed that the P28-1 T lymphocyte specificity concerned essentially the NH2 terminal sequence of the 24-43 peptide. Moreover, T lymphocytes specific for the 24-43 peptide were stimulated by both schistosome Ag and the recombinant P28-1 protein. The passive transfer of (Th + Ts) lymphocytes recovered from P28-1 Ag-immunized mice increased the IgG response to P28-1 and its peptides during infection but did not protect against a challenge infection, such as the passive transfer of anti-P28-1 sera. In contrast, P28-1 specific Th cell lines maintained in culture for 2 mo, passively transferred a strong protection (50%) to infected mice. Supernatants of P28-1-specific T cells obtained after stimulation with the corresponding Ag, were able to confer cytotoxic properties to platelets and macrophages. The presence of IFN-gamma for the cytotoxicity mediated by platelets and macrophage activating factor for the cytotoxicity mediated by macrophages in these supernatants is in a large part responsible for the parasite killing observed. Finally, a preliminary immunogenetic approach with H-2 congenic mice on BALB background showed that the P28-1 Ag T cell response was under the control of the MHC and that the H-2b haplotype determined a low response to P28-1 Ag and its peptides while H-2d and k haplotypes determined high responders.
authors.affiliation: Centre d'Immunologie et de Biologie Parasitaire, Institut Pasteur, Lille, France.
authors.forename: I
authors.initials: I
authors.lastname: Wolowczuk
authors.forename: C
authors.initials: C
authors.lastname: Auriault
authors.forename: H
authors.initials: H
authors.lastname: Gras-Masse
authors.forename: C
authors.initials: C
authors.lastname: Vendeville
authors.forename: J M
authors.initials: JM
authors.lastname: Balloul
authors.forename: A
authors.initials: A
authors.lastname: Tartar
authors.forename: A
authors.initials: A
authors.lastname: Capron
mesh_terms: D000818:Animals; D000909:Antibodies, Helminth / Q000008:administration & dosage; D000947:Antigens, Helminth / Q000008:administration & dosage* / Q000032:analysis / Q000276:immunology; D001792:Blood Platelets / Q000276:immunology; D002474:Cell-Free System; D003602:Cytotoxicity, Immunologic; D007106:Immune Sera / Q000008:administration & dosage; D007116:Immunization, Passive; D008213:Lymphocyte Activation; D008264:Macrophages / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D012555:Schistosomiasis mansoni / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D013601:T-Lymphocytes / Q000276:immunology / Q000637:transplantation; D014612:Vaccines / Q000008:administration & dosage*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000032:analysis / Q000276:immunology
chemical_list: D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D007106:Immune Sera; D014612:Vaccines; D014614:Vaccines, Synthetic